News stories about Albany Molecular Research (NASDAQ:AMRI) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Albany Molecular Research earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.135415684275 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Albany Molecular Research (AMRI) opened at 21.74 on Friday. The stock’s market capitalization is $905.82 million. The firm has a 50-day moving average of $21.72 and a 200-day moving average of $18.41. Albany Molecular Research has a one year low of $13.01 and a one year high of $22.17.

AMRI has been the subject of a number of recent analyst reports. William Blair downgraded shares of Albany Molecular Research from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 6th. J P Morgan Chase & Co downgraded shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. First Analysis cut shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday, June 12th. Finally, BidaskClub cut shares of Albany Molecular Research from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Five analysts have rated the stock with a hold rating, The company has a consensus rating of “Hold” and a consensus price target of $18.00.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/albany-molecular-research-amri-receiving-somewhat-positive-press-coverage-analysis-finds/1584521.html.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Insider Buying and Selling by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.